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Abstract
Introduction: Rational selection of disease modifying anti-rheumatic drugs in the treatment of rheumatoid arthritis
(RA) has many potential advantages, including rapid disease control, reduced long-term disability and reduced
overall cost to the healthcare system. Inter-individual genetic differences are particularly attractive as markers to
predict efficacy and toxicity, as they can be determined rapidly prior to drug selection. The aims of this study,
therefore, were to investigate the association between differences in genes associated with the metabolism,
clearance and efficacy of leflunomide with its cessation in a group of rheumatoid arthritis patients who were
treated with an intensive contemporary, treat-to-target approach.
Methods: This retrospective cohort study identified all individuals who received leflunomide and were enrolled in
the Early Arthritis inception cohort at the Royal Adelaide Hospital between 2001 and July 2011. Inclusion criteria
were age (>18) and a diagnosis of rheumatoid arthritis. Patients were excluded if a DNA sample was not available,
if they withdrew from the cohort or if clinical data were insufficient. Subjects were followed for 12 months or until
either another disease modifying antirheumatic drug was added or leflunomide was ceased. The following single
nucleotide polymorphisms (SNPs) were determined: CYP2C19*2 (rs4244285), CYP2C19*17 (rs12248560), ABCG2
421C>A (rs2231142), CYP1A2*1F (rs762551) and DHODH 19C>A (rs3213422). The effects of variables on cessation
were assessed with Cox Proportional Hazard models.
Results: Thirty-three of 78 (42.3%) patients ceased leflunomide due to side effects. A linear trend between
cytochrome P450 2C19 (CYP2C19) phenotype and leflunomide cessation was observed, with poor and intermediate
metabolizers ceasing more frequently (adjusted Hazard Ratio = 0.432 for each incremental change in phenotype,
95% CI 0.237 to 0.790, P = 0.006). Previously observed associations between cytochrome P450 1A2 (CYP1A2) and
dihydro-orotate dehydrogenase (DHODH) genotype and toxicity were not apparent, but there was a trend for ATP-
binding cassette sub-family G member 2 (ABCG2) genotype to be associated with cessation due to diarrhea.
Conclusions: CYP2C19 phenotype was associated with cessation due to toxicity, and since CYP2C19 intermediate
and poor metabolizers have lower teriflunomide concentrations, it is likely that they have a particularly poor risk:
benefit ratio when using this drug.
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Introduction
Rheumatoid arthritis (RA) is a potentially disabling form
of inflammatory arthropathy which displays both articu-
lar and systemic manifestations. Disease modifying anti-
rheumatic drugs (DMARDs) are the cornerstone of treat-
ment as they suppress underlying immune-mediated
inflammation and joint damage and prevent long-term
morbidity and mortality. Initial DMARD therapy is typi-
cally methotrexate monotherapy or a combination of
DMARDs (such as ‘triple therapy’ with methotrexate, sul-
fasalazine and hydroxychloroquine [1]). In the case of
resistant disease, therapy progresses to leflunomide and/
or biological DMARDs, such as tumor necrosis factor
(TNF) inhibitors.
Leflunomide is an effective DMARD that was intro-
duced for use principally as a single agent in RA resistant
to better established and less expensive DMARD treat-
ments. Nowadays, it is often combined with other
DMARDs after failure of initial therapy and is consider-
ably cheaper than biological DMARDs. In contrast to tra-
ditional single agent regimens, when leflunomide is used
as an adjunct to methotrexate or the other DMARD
components of ‘triple therapy’, lower doses are often
used initially and for continuing therapy. Accordingly,
there is a need to re-evaluate cessation and continuation
rates when leflunomide is used as additional therapy
when triple therapy alone has not achieved disease
control.
Because tolerance and response to leflunomide may be
influenced by polymorphisms in genes which encode
proteins involved in the metabolism and clearance of
leflunomide and its active metabolite, teriflunomide, we
have undertaken an analysis of the effect of candidate
polymorphisms on cessation/continuation rates of leflu-
nomide. Polymorphisms were chosen based on the
potential importance of proteins for which they encode
on steady state teriflunomide blood levels via an effect on
leflunomide metabolism (CYP2C19*2 (CYP2C19
681G>A, rs4244285) and CYP2C19*17 (CYP2C19,
608C>T, rs12248560) [2,3]) or biliary secretion of teriflu-
nomide (ABCG2 421C>A, rs2231142) [4,5]). Polymorph-
isms that had been linked to leflunomide toxicity
(CYP1A2*1F, (CYP1A2 163C>A, rs762551) and DHODH
(DHODH 19C>A, rs3213422) [3,6,7]) were also studied.
DHODH was also of interest because inhibition of the
encoded protein dihydro-orotate dehydrogenase
(DHODH) by teriflunomide appears to be the principal
basis of the anti-inflammatory/immunosuppressive
effects of leflunomide [8].
Identification of individuals with particularly unfavor-
able risk:benefit profiles (due to greater risk of toxicity
or resistance to therapy) should permit more rational
selection of DMARDs by minimizing both unwanted
effects and the delay to commencement of potentially
more effective, albeit more costly, therapies, such as
TNF inhibitors, which ultimately should reduce long
term joint damage and associated disability.
In a group of RA patients who were being treated with
an intensive, contemporary approach (that is, concur-
rently with other conventional DMARDs, with dose
modification according to a treat-to-target protocol [1]),
the primary aim of this cohort study was to investigate
the impact of pharmacogenomic factors on the likeli-
hood of cessation of leflunomide after adjusting for the
influence of more conventional factors.
Materials and methods
RA patient population and treatment
Patients who enrolled in the Early Arthritis inception
cohort at the Royal Adelaide Hospital who had taken
leflunomide between 2001 and July 2011 were considered
for inclusion in this study. Other inclusion criteria were
being over 18 and a diagnosis of RA according to the
1987 revised American College of Rheumatology criteria
[9]. Patients were excluded from the analysis if there was
no DNA sample available for analysis, if clinical records
were insufficient or if they withdrew from the cohort
study within the follow-up period.
Patients were treated with a standardized protocol that
has been described previously [1]. Leflunomide was
added after combination treatment had been up-titrated
(if tolerated) to the following doses: methotrexate (25 mg
sub-cutaneously per week), sulfasalazine (3 g orally daily)
and hydroxychloroquine (400 mg orally daily). During
the first three years of the cohort study, leflunomide was
introduced with a loading dose (three daily doses of 100
mg followed by 20 mg daily), and thereafter it was intro-
duced at a daily dose of 10 mg. Patients were generally
reviewed every six weeks while they had active disease, or
every three months if disease was inactive. If treatment
targets were not met while they were taking a daily leflu-
nomide dose of 10 mg, the dose was increased to 20 mg.
Data were collected for 12 months after initiation of
leflunomide.
The following information was collected at baseline:
age, gender, height, weight, smoking status, time since
diagnosis, ethnicity, use of other DMARDs, blood pres-
sure, full blood count, liver function tests, shared epitope,
anti-cyclic citrullinated peptide (anti-CCP) antibody and
rheumatoid factor titer. At each clinic visit, leflunomide
dose was recorded, patients were questioned about side
effects to all DMARDs and results of full blood count,
blood pressure readings and liver function tests were
recorded.
The duration of leflunomide was defined when the
patient had either i) ceased leflunomide due to side
effects or ii) was continuing treatment (for example, 12
months after initiation of leflunomide) and/or if another
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DMARD had been added. Leflunomide was deemed to
have been ceased due to a side effect as determined by
the patient’s clinician.
Individuals who continued to take leflunomide beyond
12 months were censored at their next clinic appoint-
ment or after 400 days (whichever was earlier), and those
who had another DMARD added were not considered to
have ceased due to side effects and were censored on the
day that the new DMARD was added and included in the
analysis.
The study was approved by the research ethics com-
mittees of the Royal Adelaide Hospital and the University
of South Australia. Patients gave informed written con-
sent to their enrolment in the Royal Adelaide Hospital
Early Arthritis inception cohort and for collection of
blood samples for DNA extraction and analysis.
Genotype evaluation
Genomic DNA was extracted from patient peripheral
blood mononuclear cells and stored at -80°C until retrie-
val. The concentration and purity of the samples was
determined using a Nanodrop (Thermo Fisher Scientific,
Waltham, MA, USA). DNA was plated into a 96-well
master plate at 5 ng/μL and stored at -20°C until
required.
The following SNPs were determined by TaqMan® SNP
genotyping assays using an ABI 7500 Fast Real-Time PCR
system (Applied Biosystems, Carlsbad, CA, USA):
CYP2C19*2 (rs4244285), CYP2C19*17 (rs12248560),
ABCG2 421C>A (rs2231142), CYP1A2*1F (rs762551) and
DHODH 19C>A (rs3213422). Assays were carried out
according to the manufacturer’s instructions.
Statistical analysis
Statistical analyses were conducted with R Version 2.13
(The R foundation for statistical computing, Vienna,
Austria). All analyses of genotypes were adjusted for vari-
ables that influenced the rate of cessation due to toxicity.
CYP2C19 was analyzed on the basis of expected pheno-
type as per the system of Pare et al. [10]. CYP2C19*2 was
considered the loss of function allele, while CYP2C19*17
was the gain of function allele. Briefly, poor metabolizers
carry two loss of function alleles, intermediate metaboli-
zers carry one loss of function and one wild-type allele,
extensive metabolizers carry two wild-type alleles and
ultra-rapid metabolizers carry either one or two gain of
function alleles and no loss of function alleles. CYP2C19
unknown metabolizers carry both a loss and gain of func-
tion allele, and were excluded from this analysis. The
CYP1A2*1F CC genotype and CYP2C19 poor metaboli-
zers had a population frequency <10%, so were pooled
with CYP1A2*1F AC genotype and CYP2C19 intermedi-
ate metabolizers respectively for analysis. Cox propor-
tional hazard models were used to estimate the Hazard
Ratio of the association between patient characteristics
and time to discontinuation of leflunomide due to side
effects. The statistical significance of the Hazard Ratio
was assessed using the likelihood ratio test. Proportional-
ity of the Hazard Ratio was assessed using the goodness-
of-fit statistic and by inspecting a plot of Schoenfeld
residuals over time. A linear trend for effect between
DHODH genotypes and CYP2C19 poor/intermediate,
extensive and ultrarapid metabolizers was assessed.
Other patient characteristics that influenced the risk of
leflunomide discontinuation were included in a multi-
variate Cox proportional hazards model to adjust for
potential confounding and to assess the incremental
effect of adding genotype or phenotype to more conven-
tional information. The effect of leflunomide dose was
assessed using a time-dependent covariate in the Cox
proportional hazards model, which indicated periods in
which a leflunomide daily dose of 10 mg or 20 mg was
being taken. Adjusted survival curves were estimated
using direct adjustment [11].
Results
From the 252 individuals who had been enrolled into
the Early Arthritis inception cohort up to July 2011, 84
were found to fulfil the inclusion criteria, and of these,
78 were included in the analysis. Of the six excluded
individuals, three had insufficient clinical data, two with-
drew from the cohort study during the follow-up period
due to diagnosis of a malignant tumor and one ceased
of their own volition due to a side effect unlikely to be
caused by leflunomide. Of the two patients who with-
drew from the cohort study, one was diagnosed with a
primary colorectal tumor which was revealed by investi-
gations undertaken after a change in bowel habit shortly
after initiation of leflunomide, and the other was diag-
nosed with metastatic lung cancer, which was identified
after 41 weeks of leflunomide treatment. The baseline
characteristics of the 78 included individuals are out-
lined in Table 1.
During the follow-up period, a total of 50 patients
(64.1%) increased their daily leflunomide dose to 20 mg
after a median of 49 days, and 4 patients (5.1%) required
addition of another DMARD due to a sub-optimal
response to leflunomide. In all, 47 individuals (60.3%)
suffered an adverse drug reaction attributable to lefluno-
mide and 33 (42.3%) ceased leflunomide due to side
effects. A total of 52 side effects that were responsible
for cessation are shown in Table 2, with diarrhea (n =
8), nausea/vomiting (n = 7) and elevated liver transami-
nases (n = 6) being the most frequently reported. The
proportion of patients still taking leflunomide over the
duration of the study is shown in Figure 1.
Patient characteristics that were significantly asso-
ciated with an altered rate of cessation were positive
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anti-CCP antibodies at the time of RA diagnosis (Hazard
Ratio = 0.43, 95% CI 0.21 to 0.92, P = 0.029) and posi-
tive rheumatoid factor at the time of RA diagnosis
(Hazard Ratio = 0.49, 95% CI 0.25 to 0.98, P = 0.044).
As expected, anti-CCP antibody was strongly correlated
with rheumatoid factor (P <0.001). Other variables that
were associated with cessation rate were current use of
a 20 mg daily dose (Hazard Ratio = 1.68, 95% CI 0.79 to
3.56) and use of triple DMARD therapy at the time of
leflunomide initiation (Hazard Ratio = 2.2, 95% CI 0.97
to 5.2), but these did not reach statistical significance
(P = 0.18 and 0.057 respectively). There was a trend for a
correlation between continuation of triple therapy with
anti-CCP antibodies (P = 0.079), but not rheumatoid
factor (P = 0.97), so positive anti-CCP antibodies were
not included in the final model.
After adjusting for current leflunomide dose, triple
therapy and positive rheumatoid factor at diagnosis,
CYP2C19 phenotype was significantly associated with the
likelihood of cessation, with ultra-rapid metabolizers
ceasing less frequently than extensive and intermediate/
poor metabolizers (Table 3 and Figure 2, Hazard Ratio =
0.432 for each incremental change in phenotype, 95% CI
0.237 to 0.790, P = 0.006). As a sensitivity analysis, non-
Caucasian subjects were removed from the analysis, and
the resultant Hazard Ratio was 0.409 (95% CI 0.219 to
0.762, P = 0.005). No association between ABCG2 (P =
0.572), CYP1A2 (P = 0.954) or DHODH (P = 0.993)
Table 1 Baseline patient characteristics (n = 78)
Age (years), median (IQR) 56.4 (48 to 66.75)
Body Mass Index (kg/m2), median (IQR) 26.6 (24.4 to 30.2)
Female 61 (78.2%)
Ever Smoked 47 (60.3%)
Current smokers 22 (28.2%)
Caucasian race 73 (93.6%)
*Continuing triple DMARD therapy 51 (65.4%)
*Continuing methotrexate 60 (76.9%)
*Continuing sulfasalazine 60 (76.9%)
*Continuing hydroxychloroquine 70 (89.7%)
Initiation of leflunomide with loading dose 7 (9.0%)
Anti-CCP antibody (n = 77) 38 (49.4%)
Rheumatoid factor 46 (59.0%)
Shared epitope (n = 76) 52 (68.4%)
Duration of disease prior to initiation of leflunomide (weeks), median (IQR) 48 (32.3 to 92.1)
DAS28 (at start of leflunomide therapy), median (IQR) 5.8 (5.2 to 6.5)
*- Participants could be included in any or all of these groups.
Table 2 Side effects leading to cessation of leflunomide











9 others‡ 1 each
* Elevated transaminases ranged from 2 to 30 times the upper limit of normal
† Includes one case each of oxidative haemolysis, neutropenia and leucopenia
‡ one each of muscle pain, blurred vision, facial flushing, mouth ulcers, taste disturbance, heavy/painful menstruation, peripheral neuropathy, loss of weight and
headaches.
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genotype and leflunomide cessation was apparent (Table
3), but interestingly, it was noted that while 0 of 14 who
had the AC genotype at 421C>A ABCG2 ceased lefluno-
mide as a result of diarrhea (+/- other side effects), 8 of
the 64 patients with the 421*CC genotype (12.5%) ceased
treatment for this reason (P = 0.198).
Discussion
Our results have shown a significant association
between CYP2C19 phenotype and cessation of lefluno-
mide due to toxicity in a group of patients with RA,
most of whom were concurrently receiving other
DMARDs.
The CYP2C19*2 loss-of-function allele (carried by
poor, intermediate or unknown metabolizers) has been
associated with lower teriflunomide concentration, which
is thought to be due to reduced conversion of lefluno-
mide to teriflunomide [3]. If the side effects from lefluno-
mide were solely caused by teriflunomide, we would
expect intermediate/poor metabolizers to have a lower
incidence of toxicity. This was not the case in this study,
and suggests either direct toxicity by leflunomide, or an
alternate pathway is competing with the conversion of
leflunomide to teriflunomide and results in formation of
another metabolite which contributes to side effects. The
latter is supported by studies of leflunomide in cultured
hepatocytes, which indicated that Cytochrome P450
mediated metabolism is a prerequisite for leflunomide
induced liver injury, whereas teriflunomide is directly,
albeit less significantly toxic [12]. Metabolites of teriflu-
nomide have not been observed in human plasma, but
studies with human liver microsomes have shown that
teriflunomide can be converted via hydroxylation to a
metabolite (M1), whereas leflunomide can be converted
to either teriflunomide or a different metabolite (M2,
also by hydroxylation) [13,14]. If the enzymes responsible
for formation of M2 are different from the well charac-
terized conversion pathway of leflunomide to terifluno-
mide, reduced activity of CYP2C19 is likely to result in
increased formation of M2, which may be the toxic meta-
bolite contributing to the side effects associated with
leflunomide.
While we provide no direct evidence for either the for-
mation of M1 or M2 in vivo or toxicity associated with
M2, we have demonstrated that CYP2C19 phenotypes
with reduced activity were associated with higher rates of
toxicity. Furthermore, since there has been an association
between greater reduction in RA disease activity in
patients with higher plasma teriflunomide steady state
Figure 1 Rates of discontinuation of leflunomide. The solid line
shows the actual rates of continuation of leflunomide and the
dashed lines the 95% confidence interval.
Table 3 Association of phenotypes and genotypes with cessation due to side effects
SNP Phenotype/Genotype Proportion ceased due to side
effects (%)
Hazard Ratio (95% Confidence
Interval), P-value*




8/15 (53.3%) 0.432 (0.237 to 0.790), P = 0.006†
Extensive metabolizers 18/39 (46.2%)
Ultra-rapid metabolizers 5/21 (23.8%)
ABCG2 421C>A (rs2231142) AC 6/14 (42.9%) 1.297 (0.527 to 3.194), P = 0.572
CC 27/64 (42.2%)
CYP1A2*1F (rs762551) AA 16/38 (42.1%) 1.021 (0.508 to 2.050), P = 0.954
AC +CC 17/40 (42.5%)
DHODH 19C>A (rs3213422) AA 9/20 (45%) 1.002 (0.610 to 1.648), P = 0.993†
AC 16/39 (41.0%)
CC 8/19 (42.1%)
All genotypes are in Hardy-Weinberg equilibrium. *after adjustment for dose, continuing triple therapy and positive rheumatoid factor. † Hazard Ratio and P-
value represent a linear test for trend. The Hazard Ratio refers to the hazard associated with each incremental change in phenotype.
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concentration [3,15,16], CYP2C19 intermediate/poor
metabolizers may have an especially adverse risk:benefit
ratio by virtue of a higher risk of cessation with side
effects and a reduced likelihood of therapeutic benefit. In
contrast, ultra-rapid metabolizers appear to have a parti-
cularly favorable risk:benefit ratio. This may be an impor-
tant factor for clinicians to consider when they are
contemplating which DMARD to prescribe their patients
with RA. This finding may also explain why there has
been no success in identifying a relationship between
adverse drug events and teriflunomide concentration.
A number of factors are considered by both physician
and patient when deciding whether to cease any medica-
tion. A novel feature of our study protocol is that a
DMARD is never stopped or switched for reason of inef-
ficacy, and the only reason to cease a DMARD is for toxi-
city. However, we must acknowledge that both patient
and physician perceptions of side effects may be subjec-
tive, and we can not exclude the possibility that inefficacy
may have influenced withdrawals. To this end, we did
not observe any association between response to lefluno-
mide after three months of treatment and CYP2C19 phe-
notype (data not shown), suggesting that reduced efficacy
is unlikely to be responsible for increased drug cessation
in CYP2C19 intermediate and poor metabolizers.
van Roon and colleagues have shown that when leflu-
nomide was given primarily as monotherapy to long term
RA patients, 29% withdrew due to an adverse event and
13% ceased due to inefficacy after a median follow-up of
317 days [17]. This compares to a withdrawal rate due to
adverse events of 42.3% in our study and addition of
another DMARD was required in 5.1% of patients. Since
our study had a shorter mean duration from diagnosis to
introduction of leflunomide (1.4 vs 9.5 years) and more
frequent use of combination DMARDs, the greater effi-
cacy and poorer tolerability observed in our cohort is to
be expected and entirely consistent with this previous
report [17].
The results of our study are in contrast to previous stu-
dies of leflunomide toxicity that have reported no relation-
ship with CYP2C19 genotype, but did demonstrate an
association with SNPs in CYP1A2 and DHODH [6,7].
There are a number of important differences in both study
design and the participants included in our study com-
pared to these previous reports (which were presumably
performed on the same patient population) which may
account for these discrepancies. First, our study was a
retrospective cohort design, which has advantages over
retrospective case control studies, which are prone to
additional selection/recruitment bias. The previous study
reported that only 19% of the group who had not ceased
leflunomide were taking another DMARD (most of whom
were also taking methotrexate), whereas the number who
ceased leflunomide while taking other DMARDs was not
reported; such a discrepancy could account for the differ-
ing rates of toxicity between genotypes, which is supported
by our finding of higher cessation rates in individuals who
were continuing triple therapy. Despite not accounting for
these important variables, the authors adjusted for factors
that did not appear to influence toxicity, such as age, body
Ultra rapid metabolizers 
Poor and intermediate metabolizers 
Extensive metabolizers 
Figure 2 Cox proportional hazard model to estimate the rates of discontinuation according to CYP2C19 phenotype (Hazard Ratio =
0.432 for each incremental change in phenotype, 95% Confidence Interval 0.237 to 0.790, P = 0.006 after adjustment for current
leflunomide dose, continuation of triple therapy and positive rheumatoid factor at diagnosis).
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mass index (BMI) and disease duration. Our approach of
adjusting only for variables that were seen to influence
cessation due to toxicity is more robust. Finally, by com-
prehensively assessing information about multiple
CYP2C19 genotypes, we were able to consider the entirety
of the information regarding CYP2C19 activity concur-
rently by comparing outcomes related to CYP2C19 pheno-
type instead of each genotype separately. This is an
important point of difference with previous studies, since
20 to 25% of individuals who carry a loss (*2) or gain (*17)
of function allele are unknown metabolizers and should,
therefore, not be considered equivalent to intermediate or
ultra-rapid metabolizers respectively. As such, compared
to CYP2C19 phenotypes, the effect size observed with
individual genotypes is likely to be lower and significant
associations are, therefore, more difficult to demonstrate.
The conversion of leflunomide to teriflunomide is
mediated by CYP1A2 (in addition to CYP2C19) [2], and
the immunosuppressive properties are mediated by inhibi-
tion of DHODH [8], but there is currently no biologically
plausible explanation for the proposed associations of
CYP1A2 and DHODH genotype and leflunomide toxicity
[6,7]. The CYP1A2*1F allele occurs in the promoter region
of the CYP1A2 gene (in intron 1), and is thought to be
important in induction of enzymatic activity in smokers
(smokers who carried one or two C residues had higher
enzyme activity compared to those who had the AA geno-
type), but it does not have an effect on enzymatic activity
in non-smokers [18]. If this mechanism is responsible for
the higher rate of adverse events, one would expect that
this SNP would only have an effect in current smokers.
Given that the current smoking rate in our cohort (28%)
was higher than that reported by Bohanec Grabar et al.
(18%) [6] a more pronounced effect on toxicity would
have been expected in our study, but this was not the case.
Smokers who carry an AC or CC genotype are likely to be
more efficient at converting lefunomide to teriflunomide,
but this does not translate to higher teriflunomide concen-
trations [3]. Furthermore, given the association between
CYP2C19 phenotype and toxicity suggests that intolerance
may be due to a toxic metabolite, enhanced CYP1A2
activity (and, therefore, enhanced conversion of lefluno-
mide to teriflunomide) is more likely to be protective of
side effects. The SNP in the DHODH gene associated with
toxicity by Grabar et al. (rs3413422) is associated with an
amino acid substitution in the expressed protein (Lys7Gln)
[7], but the effect of this on the activity of the expressed
DHODH protein is not known. While there is currently
no established biological plausibility to support the asso-
ciation of DHODH genotype and toxicity, this could
change if the functional significance of this polymorphism
is determined.
Although it was not statistically significant, reduced
activity of the ABCG2 drug efflux pump appeared to be
protective against diarrhea. This is despite individuals
with reduced ABCG2 activity having higher plasma teri-
flunomide concentrations, which is likely due to less
hepatobiliary recycling and fecal elimination [19].
Reduced secretion of teriflunomide into the gastrointest-
inal tract may be protective against diarrhea through
reduced local effect of teriflunomide on the bowel wall.
Our study did have some weaknesses that must be
acknowledged, including the retrospective design, the
assessment of patient compliance was limited to direct
questioning of study participants and one cannot be cer-
tain that all adverse events attributed to leflunomide
were both drug related and caused by leflunomide (as
opposed to one of the other DMARDs the patient was
taking concurrently). Also, where a patient ceased leflu-
nomide due to more than one side effect, no attempt was
made to ascertain the relative severity of each side effect
(and, therefore, the one primarily responsible for cessa-
tion). The small patient numbers also did not allow us to
make definitive findings regarding the factors associated
with events that occurred at low frequency within the
cohort, such as the influence of ABCG2 genotype on ces-
sation due to diarrhea.
We are not aware of any previous observations that
have linked side effects to any DMARD (including leflu-
nomide) and anti-CCP antibody and rheumatoid factor
positivity. However, it is notable that only a proportion of
cases that conform to diagnostic or classification criteria
for RA express these antibodies [9]. Accordingly, RA may
be regarded as a clinical syndrome, in which a substantial
proportion of cases have an autoimmune aetiology, as
evidenced by the presence of anti-CCP antibodies (and
rheumatoid factor with which it is strongly correlated) in
serum and synovial fluid and citrullinated peptides within
affected joints [20]. Cases that present with the RA syn-
drome but lack anti-CCP antibodies and rheumatoid fac-
tor presumably have other etiologies that, in contrast to
sero-positive RA, may be less dependent upon lympho-
cyte proliferation to sustain a chronic, pathological anti-
gen-specific immune response. The primary mechanism
of action of teriflunomide is via inhibition of DHODH,
which prevents activated T-lymphocytes from accumulat-
ing sufficient pyrimidines to support DNA synthesis,
resulting in decreased cell proliferation [14]. Since meth-
otrexate may also compromise the DHODH synthetic
pathway [21], it is conceivable that sero-positive RA is
particularly responsive to leflunomide, especially when
given as an adjunct to methotrexate therapy. In addition
to the overlapping effects of methotrexate and lefluno-
mide on pyrimidine synthesis, sulfasalazine and lefluno-
mide each have inhibitory effects on nuclear factor-B
[22,23]. These interactive effects suggest that even lower
doses of leflunomide than those used in trials hitherto
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may yield benefit and be better tolerated than current
standard doses, especially in sero-positive RA.
Informed by our observations, future research should
investigate whether leflunomide toxicity is mediated by
a toxic metabolite, and if so, seeking to identify and
quantify the putative toxic metabolite in patient plasma
as a basis for defining correlations with toxicity. Also, a
prospective evaluation of the factors that influence leflu-
nomide toxicity, which also incorporates measurement
of teriflunomide plasma concentrations would seem to
be warranted. Such a trial would ideally have higher
patient numbers through recruitment from multiple
centers that utilize structured DMARD regimens. The
value of ABCG2 genotype in predicting diarrhea should
also be assessed in a larger patient group.
Conclusions
In our group of 78 patients, most of whom were taking
triple DMARD therapy in combination with lefluno-
mide, the CYP2C19 phenotype was associated with ces-
sation due to toxicity and altered the risk:benefit ratio
when using this drug. The choice of leflunomide may,
therefore, be guided further by knowledge of CYP2C19
phenotype.
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